Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience.

Clin Sarcoma Res · 2014 · PMC4118147 · PMID 25089183

Europe PMC DOI

hedged sentence

0.2500

closest p · 5.0× alpha

0.2500

boldest claim

The sentences

a positive trendP = 0.25not close (p > 0.1)

A positive trend favouring pazopanib was also recorded in overall survival (12.5 months versus 10.7 months), without reaching a statistical significance (P = 0.25) [ 6 ].

also in 6,774 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.